15.02.2013 • NewsVaccinesbiotech industryimmunotherapy

Anergis Expands Management Team

Anergis, a company developing breakthrough allergy vaccines for fast and safe allergen-specific immunotherapy, today announced the expansion of its management team. With the appointments of Gilles Della Corte as Director of Clinical Development and Eva Castagnetti as Director of Product Development, the company has significantly strengthened its late-stage drug development expertise.

Gilles Della Corte, MD, brings to Anergis extensive expertise in global clinical development. In the past 22 years, he worked both for pharmaceutical companies, including Rhone-Poulenc Rorer, Servier, Solvay Pharma, Serono and Merck Serono, and for CROs where he held various senior positions in Research and Development.

Eva Castagnetti, PhD, has several years of experience in both technical and business management functions in the biopharmaceutical industry with Lonza, Senn Chemicals and Rapid Pharmaceuticals.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.